skip to content
Skip Navigation
Suven Life Sciences

Drug Discovery & Development Support Services (DDDSS)

Suven Life Sciences provides wide range of Drug Discovery and Development Support Services to global Pharma and Biotech companies. Suven has state-of-art facilities with highly qualified & experienced team of scientists.

Read More..

Drug Discovery & Research/Clinical pipeline

Suven discovery research is focused on discovering and developing new chemical entities (NCEs), which are best in class central nervous system therapies for the treatment of a diverse range of disorders.

Read More..

News/Events

  • Suven Life Sciences to Present Positive Results from Phase-2a Proof-of-Concept Study of Ropanicant (SUVN-911) and Updates on Innovation Pipeline Assets at Neuroscience 2024, Chicago, USA
  • Suven Life Sciences Announces Positive Topline Results from Phase-2a Proof-of-Concept Signal Detection Open Label Study of Ropanicant (SUVN-911) for the Treatment of Moderate to Severe Major Depressive Disorder (MDD)
  • Suven Life Sciences Announces FDA acceptance of Investigational New Drug (IND) and grant of “Study may proceed Letter” to initiate Phase-1 Clinical Trial of SUVN-I6107, a True Muscarinic M1 Receptor Positive Allosteric Modulator (M1-PAM)
  • Suven Life Sciences Announces Clinical and Preclinical Presentations at the Alzheimer’s Association International Conference (AAIC) 2024 in Philadelphia, USA
  • Suven Life Sciences to Present New Data Analyses from Samelisant Phase-2 Study Results at the SLEEP 2024 Annual Meeting,Houston,USA
  • Suven Life Sciences to Present Ropanicant Baseline data at 2024 American Society of Clinical ASCP Conference, Miami, USA
  • Suven Life Sciences to present Phase-2 Positive Results on Samelisant (SUVN-G3031) at American Acade
  • Suven Life Sciences Announces Randomization of First Patient in Phase-2 POC Clinical Trial of Ropani
  • BM Outcome 30.01.2024
  • Clarification on Increase in Price
  • Clarification on Increase in volume
More >>

Latest Events